StockData
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc. (FLNA) stock

FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$0.64+0.08 (+14.52%)

Close on Nov 20, 2026Market cap $30.98MP/E –Yield –

Filana Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Filana Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$32.83M. For fiscal 2025 it was -$32.83M. The highest annual figure on record is -$2.53M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.83M–
FY2024Dec 31, 2024-$117.03M–
FY2023Dec 31, 2023-$82.44M–
FY2022Dec 31, 2022-$80.23M–
FY2021Dec 31, 2021-$52.41M–
FY2019Dec 31, 2019-$2.53M–
FY2016Dec 31, 2016-$12.31M–
FY2015Dec 31, 2015-$9.25M–
FY2014Dec 31, 2014-$9.63M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$10.25M–
Q3 FY2025Sep 30, 2025-$6.30M–
Q2 FY2025Jun 30, 2025-$4.95M–
Q1 FY2025Mar 31, 2025-$11.34M–
Q4 FY2024Dec 31, 2024-$61.32M–
Q3 FY2024Sep 30, 2024-$18.31M–
Q2 FY2024Jun 30, 2024-$18.27M–
Q1 FY2024Mar 31, 2024-$19.13M–
Q4 FY2023Dec 31, 2023-$22.36M–
Q3 FY2023Sep 30, 2023-$26.55M–
Q2 FY2023Jun 30, 2023-$19.92M–
Q1 FY2023Mar 31, 2023-$13.61M–
Q4 FY2022Dec 31, 2022-$20.99M–
Q3 FY2022Sep 30, 2022-$22.71M–
Q2 FY2022Jun 30, 2022-$12.58M–
Q1 FY2022Mar 31, 2022-$23.96M–
Q4 FY2021Dec 31, 2021-$8.09M–
Q3 FY2021Sep 30, 2021-$36.81M–
Q4 FY2019Dec 31, 2019-$589.00K–
Q3 FY2019Sep 30, 2019-$730.00K–
Q2 FY2019Jun 30, 2019-$591.00K–
Q1 FY2019Mar 31, 2019-$622.00K–
Q4 FY2016Dec 31, 2016-$3.03M–

More Filana Therapeutics figures

See a number that looks wrong?